/SBFM
SBFM Stock - Sunshine Biopharma, Inc.
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$1.39+1.83%
+$0.03 (+1.83%) • Dec 19
58
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.20
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.90
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.53
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SBFM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.38 – $1.40
TARGET (TP)$1.60
STOP LOSS$1.28
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.74
52W High$3.90
52W Low$1.17
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $34.87M | $24.09M | $4.35M | $228,426 | $71,410 |
| Gross Profit | $10.67M | $8.34M | $1.70M | $110,596 | $45,563 |
| Gross Margin | 30.6% | 34.6% | 39.0% | 48.4% | 63.8% |
| Operating Income | $-5,812,000 | $-4,785,000 | $-27,001,000 | $-2,440,000 | $-576,874 |
| Net Income | $-5,134,000 | $-4,506,000 | $-26,744,000 | $-12,436,000 | $-2,784,091 |
| Net Margin | -14.7% | -18.7% | -615.4% | -5444.2% | -3898.7% |
| EPS | $-7.32 | $-351.36 | $-3523.64 | $-9774.32 | $-3214.89 |
Company Overview
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
SBFMBeat Rate
13%
Last 8 quarters
Avg Surprise
-17572.9%
EPS vs Estimate
Beats / Misses
1/7
Last 12 quarters
Latest EPS
$-0.19
Q4 2025
EPS Surprise History
Q4 23
-133233.3%
$-80.00vs$-0.06
Q1 24
-3233.3%
$-100.00vs$-3.00
Q2 24
-3746.2%
$-40.00vs$-1.04
Q3 24
-34.3%
$-9.94vs$-7.40
Q4 24
-110.4%
$-0.94vs$9.00
Q2 25
No data
Q3 25
-254.5%
$-0.39vs$-0.11
Q4 25
-46.2%
$-0.19vs$-0.13
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.13 | $-0.19 | -46.2% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | $-0.11 | $-0.39 | -254.5% | ✗ MISS |
Q2 2025 | May 15, 2025 | — | $-0.44 | — | — |
Q4 2024 | Nov 5, 2024 | $9.00 | $-0.94 | -110.4% | ✗ MISS |
Q3 2024 | Aug 16, 2024 | $-7.40 | $-9.94 | -34.3% | ✗ MISS |
Q2 2024 | May 20, 2024 | $-1.04 | $-40.00 | -3746.2% | ✗ MISS |
Q1 2024 | Mar 28, 2024 | $-3.00 | $-100.00 | -3233.3% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $-0.06 | $-80.00 | -133233.3% | ✗ MISS |
Q3 2023 | Aug 11, 2023 | $-160.00 | $-40.00 | +75.0% | ✓ BEAT |
Q2 2023 | May 10, 2023 | — | $-160.00 | — | — |
Q2 2023 | Apr 4, 2023 | — | $-3000.00 | — | — |
Q4 2022 | Nov 7, 2022 | — | $-160.00 | — | — |
Q3 2022 | Aug 3, 2022 | — | $-60.00 | — | — |
Q2 2022 | May 6, 2022 | — | $-0.23 | — | — |
Q1 2022 | Mar 21, 2022 | — | $0.19 | — | — |
Q4 2021 | Nov 9, 2021 | — | $-1.59 | — | — |
Q3 2021 | Aug 9, 2021 | — | $-1.20 | — | — |
Q2 2021 | May 11, 2021 | — | $-2.82 | — | — |
Q1 2021 | Mar 30, 2021 | — | $-0.63 | — | — |
Latest News
Sunshine Biopharma's Nora Pharma Gains Canadian FDA-Equivalent Clearance For Domperidone Used In Chemotherapy-Induced Nausea
📈 PositiveBenzinga•Oct 28, 2025, 11:49 AM
Sunshine Biopharma Announces Commercial Launch Of Generic Doxycycline In Canada
📈 PositiveBenzinga•Oct 20, 2025, 11:46 AM
Sunshine Biopharma shares are trading higher after the company announced its subsidiary, Nora Pharma, launched Pravastatin.
📈 PositiveBenzinga•Oct 16, 2025, 01:12 PM
Sunshine Biopharma Canadian Subsidiary, Nora Pharma, Launches Pravastatin, Generic Prescription Drug In Therapeutic Class Of Lipid Metabolism Regulators
📈 PositiveBenzinga•Oct 16, 2025, 11:55 AM
Sunshine Biopharma To Allocate $5M For Investment An Bitcoin As Reserve Asset
📈 PositiveBenzinga•Oct 14, 2025, 11:06 AM•Also: , ,
Sunshine Biopharma In Collaboration With University Of Arizona Announces Development Of New Series Of Orally Active, Non-Covalent Protease Inhibitors That Show Dose-Dependent Antiviral Activity In Mice Infected With Sars-CoV-2
📈 PositiveBenzinga•Oct 9, 2025, 12:02 PM
Aegis Capital Reiterates Buy on Sunshine Biopharma, Maintains $7 Price Target
📈 PositiveBenzinga•Oct 8, 2025, 04:46 PM
Sunshine Biopharma Filed U.S. Patent Application #20250276036 For "COMPOSITION FOR THE INHIBITION OF NRF2 AND USES THEREOF IN CANCER THERAPY"
📈 PositiveBenzinga•Sep 4, 2025, 08:00 PM
Sunshine Biopharma launches generic Gabapentin for neuropathic pain in Canada
📈 PositiveSeeking Alpha•Jun 11, 2025, 12:45 PM
Frequently Asked Questions about SBFM
What is SBFM's current stock price?
Sunshine Biopharma, Inc. (SBFM) is currently trading at $1.39 per share. The stock has moved +1.83% today.
What is the analyst price target for SBFM?
No analyst price targets are currently available for this stock.
What sector is Sunshine Biopharma, Inc. in?
Sunshine Biopharma, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is SBFM's market cap?
Sunshine Biopharma, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does SBFM pay dividends?
No, Sunshine Biopharma, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACXP
Acurx Pharmaceuticals, Inc.
$3.33
Mkt Cap: $0.0B
BFRI
Biofrontera Inc.
$0.77
Mkt Cap: $0.0B
CHEK
Check-Cap Ltd.
$1.61
Mkt Cap: $0.0B
EVOK
Evoke Pharma, Inc.
$11.00
Mkt Cap: $0.0B
HCWB
HCW Biologics Inc.
$1.57
Mkt Cap: $0.0B
IINN
Inspira Technologies Oxy B.H.N. Ltd.
$1.02
Mkt Cap: $0.0B
LUCY
Innovative Eyewear, Inc.
$1.38
Mkt Cap: $0.0B
PFSA
Profusa, Inc. Common Stock
$0.12
Mkt Cap: $0.0B
SNOA
Sonoma Pharmaceuticals, Inc.
$3.57
Mkt Cap: $0.0B
YCBD
cbdMD, Inc.
$1.51
Mkt Cap: $0.0B
Explore stocks similar to SBFM for comparison